Evidence Synthesis
Here is the standard_shift narrative based on the provided payload: Dr Reddy Laboratories (DRREDDY) has seen a significant shift in its financials, with its gross margin accelerating to 52.77%, up from 1.54%.
This improvement is a notable change from its previous quarter, where the gross margin was 25.29%.
In terms of revenue growth, the company has seen a deceleration in its revenue growth yoy, moving from -86.2 % to -11.6 % (quarterly cadence).
The company's close price has also seen a decline, moving from 1367.9 INR to (daily cadence).
On the other hand, the company's marginal operating leverage has seen a deceleration, moving from 12.76 % to 1.54 % (quarterly cadence).
The daily volume has also seen a decline, moving from 2458580 shares to (daily cadence).